| abstract |
The invention relates to mono-or poly-epitopic peptide compounds of sequence SEQ ID No. 1 to 16 and their analogous derivatives, muteins and homologues, for the prevention and treatment of leishmaniasis in mammals and in particular in the Man, canines, felids and equines. More particularly, the invention also relates to vaccines comprising said peptide compounds under conditions ensuring immunization leading to effective protection of the human or vaccinated animal against one or more leishmanias. |